Stocks: Sumitomo Mitsui Asset Management Company LTD Boosts Stake in Davita Inc (DVA)

Stocks: Sumitomo Mitsui Asset Management Company LTD Boosts Stake in Davita Inc (DVA)

Sumitomo Mitsui Asset Management Company LTD raised its stake in Davita Inc (NYSE:DVA) by 9.6% during the first quarter, according to its most recent filing with the SEC. The fund owned 13,843 shares of the company’s stock after buying an additional 1,213 shares during the period. Sumitomo Mitsui Asset Management Company LTD’s holdings in Davita were worth $940,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the company. SRS Capital Advisors Inc. purchased a new position in Davita during the fourth quarter worth $118,000. Raymond James Trust N.A. purchased a new position in Davita during the first quarter worth $202,000. Seven Bridges Advisors LLC boosted its position in Davita by 187.1% in the third quarter. Seven Bridges Advisors LLC now owns 3,066 shares of the company’s stock worth $203,000 after buying an additional 1,998 shares during the period. Wetherby Asset Management Inc. boosted its position in Davita by 3.3% in the first quarter. Wetherby Asset Management Inc. now owns 3,224 shares of the company’s stock worth $219,000 after buying an additional 104 shares during the period. Finally, Parametrica Management Ltd purchased a new position in Davita during the first quarter worth $237,000. Institutional investors own 85.31% of the company’s stock.

Davita Inc (NYSE:DVA) traded down 0.16% during mid-day trading on Friday, hitting $66.77. 43,084 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $67.56 and its 200-day moving average price is $65.04. Davita Inc has a one year low of $54.50 and a one year high of $78.77. The stock has a market cap of $12.99 billion, a PE ratio of 10.97 and a beta of 1.02.

Davita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, May 2nd. The company reported $0.79 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.82 by $0.03. Davita had a net margin of 4.92% and a return on equity of 16.16%. The company had revenue of $3.70 billion during the quarter, compared to analysts’ expectations of $3.69 billion. On average, analysts forecast that Davita Inc will post $3.55 EPS for the current fiscal year.

DVA has been the topic of a number of analyst reports. TheStreet upgraded shares of Davita from a “c+” rating to a “b-” rating in a research report on Monday, April 3rd. Zacks Investment Research raised shares of Davita from a “hold” rating to a “buy” rating and set a $77.00 target price for the company in a research note on Tuesday, April 18th. Finally, Royal Bank of Canada reissued a “hold” rating and set a $62.00 target price on shares of Davita in a research note on Friday, February 17th. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $70.33.

In related news, Director William L. Roper sold 12,994 shares of the stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $65.89, for a total transaction of $856,174.66. Following the transaction, the director now directly owns 45,277 shares in the company, valued at $2,983,301.53. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Charles Berg sold 8,414 shares of the stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $65.80, for a total value of $553,641.20. Following the transaction, the director now owns 34,719 shares in the company, valued at $2,284,510.20. The disclosure for this sale can be found here. 2.10% of the stock is owned by corporate insiders.

Davita Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).

Related posts

Leave a Comment